Form 4: Protara Therapeutics Director Barry Flannelly Granted 24,000 Stock Options

Protara Therapeutics, Inc. Director Barry P. Flannelly was granted 24,000 stock options with an exercise price of $3.26, vesting on the first anniversary of the grant date or upon a change of control.

Summary

• Barry P. Flannelly, a Director of Protara Therapeutics, Inc. (TARA), was granted 24,000 stock options.
• The options have an exercise price of $3.26 per share.
• The grant date for these options was June 12, 2025.
• The options will vest in full on June 12, 2026, which is the first anniversary of the grant date, provided Mr. Flannelly maintains continuous service on the Board.
• Additionally, the options will vest immediately in full upon a Change of Control event.
• The options have an expiration date of June 11, 2035.
• Following this transaction, Mr. Flannelly beneficially owns 24,000 derivative securities (stock options) directly.

Sentiment

Score: 6

Explanation: The grant of stock options to a director is a routine event that aligns interests, generally viewed as neutral to slightly positive as it incentivizes performance without direct cash outflow.

Positives

• The grant of stock options aligns the director's interests with those of shareholders, incentivizing long-term company performance.
• The vesting schedule encourages continued service by the director.
• The change of control vesting provision provides an incentive for the director during potential acquisition scenarios.

Risks

• The value of the stock options is dependent on the future stock price of Protara Therapeutics, Inc. exceeding the exercise price of $3.26. If the stock price does not increase, the options may expire worthless.
• The vesting is subject to continuous service, meaning the director must remain on the board for the options to vest on the anniversary date.

Future Outlook

The document indicates future vesting of stock options on June 12, 2026, or upon a change of control, aligning the director's future incentives with company performance.

Industry Context

This is a standard equity compensation grant to a director, a common practice across publicly traded companies in various industries, including biotechnology, to align director incentives with shareholder value creation.

Comparison to Industry Standards

• The grant of 24,000 stock options to a director with a vesting period and an exercise price is a common form of non-cash compensation in the biotechnology and pharmaceutical sectors, similar to practices seen at comparable small-to-mid cap biotech firms.
• The specific value and quantity would typically be benchmarked against peer group compensation data, though such comparative data is not provided in this filing.

Corporate Governance

Related Party Transactions

• The grant of stock options to a director, Barry P. Flannelly, constitutes a transaction with a related party, as directors are considered related parties to the company.

Stakeholder Impact

• Shareholders: The grant aligns the director's interests with shareholders, potentially leading to better long-term performance. It also represents a potential future dilution if options are exercised, though this is standard for equity compensation.

Next Steps

• The stock options will vest on June 12, 2026, subject to continuous service.
• The stock options will vest upon a Change of Control.
• The director may exercise the options at any time after vesting and before the expiration date of June 11, 2035.

Key Dates

Keywords

Protara Therapeutics, TARA, SEC Form 4, stock options, director compensation, equity grant, beneficial ownership, insider transaction, Barry P Flannelly